Lucence Health Inc.
Lucence HemeMark - Next-generation Sequencing (NGS) Assay
HemeMARK™ is a next-generation sequencing assay that analyzes 45 cancer-related gene mutations in hematological malignancies including myeloid and lymphoid neoplasms.
Most popular related searches
HemeMARK detects a wide range of mutation types – single nucleotide variants (including cis-trans), short insertions and deletions (indels),copy number variants (CNVs),microsatellite instability (MSI),and the BCR/ABL1 fusion